Compugen Ltd (CGEN): Total Assets
$156.57M
As of 2025-12-31
+18.5%
3-year compound annual growth
+2.5%
5-year compound annual growth
+4.7%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $156.57M | +36.2% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $115.00M | -5.2% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $121.33M | +28.8% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $94.18M | -28.7% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $132.16M | -4.4% | 2023-08-23, Balance as of period end |
| 2020-12-31 | $138.32M | +157.3% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $53.76M | +1.1% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $53.18M | +37.3% | 2020-02-24, Balance as of period end |
| 2017-12-31 | $38.75M | -45.5% | 2019-03-21, Balance as of period end |
| 2016-12-31 | $71.14M | -28.4% | 2018-03-27, Balance as of period end |
| 2015-12-31 | $99.31M | -13.6% | 2017-02-16, Balance as of period end |
| 2014-12-31 | $114.99M | +102.8% | 2016-03-07, Balance as of period end |
| 2013-12-31 | $56.71M | +96.2% | 2015-03-12, Balance as of period end |
| 2012-12-31 | $28.91M | -0.6% | 2014-02-18, Balance as of period end |
| 2011-12-31 | $29.08M | -20.2% | 2013-03-21, Balance as of period end |
| 2010-12-31 | $36.46M | n/a | 2012-03-14, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Compugen Ltd (CGEN) | 2025-12-31 | $156.57M | +36.2% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $1.47B | +1.8% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $589.07M | -24.7% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $143.01M | +16.6% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $1.00B | -28.3% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $244.43M | -9.4% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $566.71M | +1.1% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $276.88M | +113.8% |
Compare CGEN, RXRX, AUTL, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗